Search research articles
Contact Us
Filters
Showing results (141-150 of 234) with videos related to
Page
of 24
Sort By:
Anti-Cancer Drugs
|
June 6, 2008
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis
Amir Mearadji, Michael A den Bakker, Albertus N van Geel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2012
The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin
Marijn T M van Jaarsveld, Iris C J Blijdorp, Antonius W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2005
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors
Maja J A de Jonge, Ate van der Gaast, André S T Planting, et al.
The Oncologist
|
May 2, 2008
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
Isabelle Ray-Coquard, Axel Le Cesne, Jeremy S Whelan, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2004
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group
Ian Judson, Peiming Ma, Bin Peng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors
Helen J Mackay, Ronald Hoekstra, Ferry A L M Eskens, et al.
Cancer Biology & Therapy
|
June 23, 2005
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
Herman Burger, Hans van Tol, Mariël Brok, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 16, 2005
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
John R Zalcberg, Jaap Verweij, Paolo G Casali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2008
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
Nielka van Erp, Hans Gelderblom, Martine van Glabbeke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 17, 2003
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
Allan T van Oosterom, Ian R Judson, Jaap Verweij, et al.
Page
of 24
Search research articles
Search
Showing results (141-150 of 234) with videos related to
Sort By:
Page
of 24
Anti-Cancer Drugs
|
June 6, 2008
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis
Amir Mearadji, Michael A den Bakker, Albertus N van Geel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2012
The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin
Marijn T M van Jaarsveld, Iris C J Blijdorp, Antonius W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2005
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors
Maja J A de Jonge, Ate van der Gaast, André S T Planting, et al.
The Oncologist
|
May 2, 2008
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
Isabelle Ray-Coquard, Axel Le Cesne, Jeremy S Whelan, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2004
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group
Ian Judson, Peiming Ma, Bin Peng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors
Helen J Mackay, Ronald Hoekstra, Ferry A L M Eskens, et al.
Cancer Biology & Therapy
|
June 23, 2005
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
Herman Burger, Hans van Tol, Mariël Brok, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 16, 2005
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
John R Zalcberg, Jaap Verweij, Paolo G Casali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2008
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
Nielka van Erp, Hans Gelderblom, Martine van Glabbeke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 17, 2003
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
Allan T van Oosterom, Ian R Judson, Jaap Verweij, et al.
Page
of 24